KMT2A and acute lymphoblastic leukemia: Although GC is a key agent for targeting lymphoid malignancies, basic experimental studies showed that MLL-ALL cells become rapidly resistant to GCs in vitro [[15], [16], [17], [18], [19], [20], [21], [22]] an in vivo [3,18,20,21].